

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7893659

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST
CONVEYING PARTY DATA	
Name	Execution Date
BIOCRYST PHARMACEUTICALS, INC.	12/07/2020
RECEIVING PARTY DATA	
Name:	ATHYRIUM OPPORTUNITIES III CO-INVEST 1 LP
Street Address:	505 FIFTH AVENUE
Internal Address:	FLOOR 18
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10017
PROPERTY NUMBERS Total: 15	
Property Type	Number
Patent Number:	11110092
Patent Number:	10689346
Patent Number:	11021458
Patent Number:	11464755
Patent Number:	11173159
Patent Number:	10622160
Patent Number:	10933066
Patent Number:	11066360
Patent Number:	11117867
Patent Number:	11192861
Patent Number:	11203574
Patent Number:	11230530
Application Number:	16987721
Patent Number:	11559515
PCT Number:	US2019059385
CORRESPONDENCE DATA	
Fax Number:	(310)551-8741
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	

Phone: 3105518755
Email: pto-cc@gibsondunn.com
Correspondent Name: MANDY ROBERTSON-BORA
Address Line 1: 2029 CENTURY PARK EAST, SUITE 4000
Address Line 4: LOS ANGELES, CALIFORNIA 90067-3026

ATTORNEY DOCKET NUMBER: 12412-00023

NAME OF SUBMITTER: MANDY ROBERTSON-BORA

SIGNATURE: /mandy robertson-bora/

DATE SIGNED: 04/10/2023

Total Attachments: 65

source=2020-12-07 Security Interest#page1.tif
source=2020-12-07 Security Interest#page2.tif
source=2020-12-07 Security Interest#page3.tif
source=2020-12-07 Security Interest#page4.tif
source=2020-12-07 Security Interest#page5.tif
source=2020-12-07 Security Interest#page6.tif
source=2020-12-07 Security Interest#page7.tif
source=2020-12-07 Security Interest#page8.tif
source=2020-12-07 Security Interest#page9.tif
source=2020-12-07 Security Interest#page10.tif
source=2020-12-07 Security Interest#page11.tif
source=2020-12-07 Security Interest#page12.tif
source=2020-12-07 Security Interest#page13.tif
source=2020-12-07 Security Interest#page14.tif
source=2020-12-07 Security Interest#page15.tif
source=2020-12-07 Security Interest#page16.tif
source=2020-12-07 Security Interest#page17.tif
source=2020-12-07 Security Interest#page18.tif
source=2020-12-07 Security Interest#page19.tif
source=2020-12-07 Security Interest#page20.tif
source=2020-12-07 Security Interest#page21.tif
source=2020-12-07 Security Interest#page22.tif
source=2020-12-07 Security Interest#page23.tif
source=2020-12-07 Security Interest#page24.tif
source=2020-12-07 Security Interest#page25.tif
source=2020-12-07 Security Interest#page26.tif
source=2020-12-07 Security Interest#page27.tif
source=2020-12-07 Security Interest#page28.tif
source=2020-12-07 Security Interest#page29.tif
source=2020-12-07 Security Interest#page30.tif
source=2020-12-07 Security Interest#page31.tif
source=2020-12-07 Security Interest#page32.tif
source=2020-12-07 Security Interest#page33.tif
source=2020-12-07 Security Interest#page34.tif
source=2020-12-07 Security Interest#page35.tif
source=2020-12-07 Security Interest#page36.tif

source=2020-12-07 Security Interest#page37.tif
source=2020-12-07 Security Interest#page38.tif
source=2020-12-07 Security Interest#page39.tif
source=2020-12-07 Security Interest#page40.tif
source=2020-12-07 Security Interest#page41.tif
source=2020-12-07 Security Interest#page42.tif
source=2020-12-07 Security Interest#page43.tif
source=2020-12-07 Security Interest#page44.tif
source=2020-12-07 Security Interest#page45.tif
source=2020-12-07 Security Interest#page46.tif
source=2020-12-07 Security Interest#page47.tif
source=2020-12-07 Security Interest#page48.tif
source=2020-12-07 Security Interest#page49.tif
source=2020-12-07 Security Interest#page50.tif
source=2020-12-07 Security Interest#page51.tif
source=2020-12-07 Security Interest#page52.tif
source=2020-12-07 Security Interest#page53.tif
source=2020-12-07 Security Interest#page54.tif
source=2020-12-07 Security Interest#page55.tif
source=2020-12-07 Security Interest#page56.tif
source=2020-12-07 Security Interest#page57.tif
source=2020-12-07 Security Interest#page58.tif
source=2020-12-07 Security Interest#page59.tif
source=2020-12-07 Security Interest#page60.tif
source=2020-12-07 Security Interest#page61.tif
source=2020-12-07 Security Interest#page62.tif
source=2020-12-07 Security Interest#page63.tif
source=2020-12-07 Security Interest#page64.tif
source=2020-12-07 Security Interest#page65.tif

NOTICE
OF
GRANT OF SECURITY INTEREST
IN
PATENTS

United States Patent and Trademark Office

December 7, 2020

Ladies and Gentlemen:


Please be advised that pursuant to the Security Agreement dated as of December 7, 2020 (as the same may be amended, modified, restated or supplemented from time to time, the "Security Agreement") by and among the Grantors party thereto (each a "Grantor" and collectively, the "Grantors") and ATHYRIUM OPPORTUNITIES III CO-INVEST 1 LP, as Administrative Agent (the "Administrative Agent") for the Secured Parties referenced therein, the undersigned Grantor has granted a continuing security interest in and continuing lien upon, any and all of its patents, patent licenses and patent applications, including those patents, patent licenses and patent applications set forth on Schedule 1 attached hereto to the Administrative Agent for the ratable benefit of the Secured Parties.

The undersigned Grantor and the Administrative Agent, on behalf of the Secured Parties, hereby acknowledge and agree that the security interest in the patents, patent licenses and patent applications of the undersigned Grantor, including those set forth on Schedule 1 attached hereto (i) may only be terminated in accordance with the terms of the Security Agreement and (ii) is not to be construed as an assignment of any patent, patent license or patent application.

[Signature pages follow]

Very truly yours,

BIOCRIST PHARMACEUTICALS, INC.,
a Delaware corporation

By: 
Name: Anthony Doyle
Title: Chief Financial Officer

[Signature Page—Notice of Grant of Security Interest in Patents]

ATHYRIUM OPPORTUNITIES III CO-INVEST 1 LP,
a Delaware limited partnership, as Administrative Agent

By: Athyrium Opportunities Associates Co-Invest LLC,
a Delaware limited liability company, its general partner

By: Rashida Adams
Name: Rashida Adams
Title: Authorized Signatory

Schedule 1

See attached.

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Substituted Cyclopentane and Cyclopentene Compounds Useful as Neuraminidase Inhibitors	Australia	2003212040	Granted	12/17/1998	12/17/2023
BioCryst	Substituted Cyclopentane and Cyclopentene Compounds Useful as Neuraminidase Inhibitors	Canada	2315262	Granted	12/17/1998	12/17/2018 (expired)

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP ¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date ²	Projected Expiration Date ³
BioCryst	Substituted Cyclopentane and Cyclopentene Compounds Useful as Neuraminidase Inhibitors	EPO (European Patent Office)	1040094	Granted* *Validated in AT, BE, CH/LI, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, and SE, plus AL, LT, LV, MK, RO, and SI	12/17/1998	12/17/2018* * Supplementary Protection Certificates (SPCs) have been granted in available EU countries, extending this patent's protection for peramivir and pharmaceutically active salts thereof to 12/16/2023 in FR, GB, IE, and NL, to 12/17/2023 in AT, BE, CY, DK, FI, DE, IT, LV, LT, LU, PT, RO, SI, ES, and SE, and to 12/18/2023 in GR.
BioCryst	Substituted Cyclopentane and Cyclopentene Compounds Useful as Neuraminidase Inhibitors	Japan	4102022	Granted	12/17/1998	10/02/2020 (expired)

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Substituted Cyclopentane and Cyclopentene Compounds Useful as Neuraminidase Inhibitors	Japan	5118502	Granted	12/17/1998	12/17/2018 (expired)
BioCryst	Substituted Cyclopentane and Cyclopentene Compounds Useful as Neuraminidase Inhibitors	Japan	5709688	Granted	12/17/1998	12/17/2018 (expired)
BioCryst	Substituted Cyclopentane and Cyclopentene Compounds Useful as Neuraminidase Inhibitors	Poland	196674	Granted	12/17/1998	12/17/2018* *SPC has been granted, extending this patent's protection for peramivir and pharmaceutically active salts thereof to 12/17/2023.
BioCryst	Substituted Cyclopentane and Cyclopentene Compounds Useful as Neuraminidase Inhibitors	Romania	121815	Granted	12/17/1998	12/17/2018 (expired)

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Substituted Cyclopentane and Cyclopentene Compounds Useful as Neuraminidase Inhibitors	US	6,562,861	Granted	12/17/1998	12/16/2023
BioCryst	Intravenous Antiviral Treatments	Australia	2013216632	Granted	02/12/2007	02/12/2027
BioCryst	Intravenous Antiviral Treatments	Australia	2016262644	Granted	02/12/2007	02/12/2027
BioCryst	Intravenous Antiviral Treatments	Brunei	RE/R/2019/0008	Granted (re-registration of MY-166063-A, below)	02/12/2007	02/12/2027
BioCryst	Intravenous Antiviral Treatments	Brazil	PI0707769-6	Pending	02/12/2007	02/12/2027
BioCryst	Intravenous Antiviral Treatments	Canada	2642260	Granted	02/12/2007	02/12/2027
BioCryst	Intravenous Antiviral Treatments	China	201510115375.7	Pending	02/12/2007	02/12/2027

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Intravenous Antiviral Treatments	Eurasia	025483	Granted*	02/12/2007	02/12/2027
				*Maintained in Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Russian Federation, Tajikistan, and Turkmenistan		
BioCryst	Intravenous Antiviral Treatments	Hong Kong	16100369.5	Pending	02/12/2007	02/12/2027
BioCryst	Intravenous Antiviral Treatments	Indonesia	IDP000046170	Granted	02/12/2007	02/12/2027
BioCryst	Intravenous Antiviral Treatments	Japan	6073202	Granted	02/12/2007	02/12/2027
BioCryst	Intravenous Antiviral Treatments	Republic of Korea	10-1992585 (10-2018-7005451)	Granted	02/12/2007	02/12/2027
BioCryst	Intravenous Antiviral Treatments	Republic of Korea	10-2019-7017311	Allowed	02/12/2007	02/12/2027
BioCryst	Intravenous Antiviral Treatments	Malaysia	MY-166063-A (P120083086)	Granted	02/12/2007	02/12/2027
BioCryst	Intravenous Antiviral Treatments	Mexico	328727	Granted	02/12/2007	02/12/2027
BioCryst	Intravenous Antiviral Treatments	Mexico	371883 (MX/a/2014/010266)	Granted	02/12/2007	02/12/2027

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Intravenous Antiviral Treatments	Mexico	MX/a/2020/002008	Pending	02/12/2007	02/12/2027
BioCryst	Intravenous Antiviral Treatments	New Zealand	570538	Granted	02/12/2007	02/12/2027
BioCryst	Intravenous Antiviral Treatments	Singapore	145235	Granted	02/12/2007	02/12/2027
BioCryst	Intravenous Antiviral Treatments	South Africa	2008/09012	Granted	02/12/2007	02/12/2027
BioCryst	Intravenous Antiviral Treatments	Vietnam	1-2008-02252	Pending	02/12/2007	02/12/2027
BioCryst	Intravenous Antiviral Treatments	US	8,778,997	Granted	02/12/2007*	05/07/2027
BioCryst	Antiviral Treatments	US	9,770,427	Granted	02/12/2007*	02/12/2027
BioCryst	Antiviral Treatments	US	10,391,075 (15/714,918)	Granted	02/12/2007*	02/12/2027
BioCryst	Antiviral Treatments	US	16/533,283	Pending	02/12/2007*	02/12/2027
BioCryst	Process for Preparing Substituted Cyclopentane Derivatives and Novel Crystalline Structures Thereof	US	6,503,745	Granted	11/05/1999	11/05/2019 (expired)

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Process for Preparing Substituted Cyclopentane Derivatives and Novel Crystalline Structures Thereof	Japan	4262920	Granted	06/09/2000	05/02/2021
BioCryst	Process for Preparing Substituted Cyclopentane Derivatives and Novel Crystalline Structures Thereof	Japan	4597237	Granted	06/09/2000	06/09/2020 (expired)
BioCryst	Process for Preparing Substituted Cyclopentane Derivatives and Novel Crystalline Structures Thereof	Poland	213231	Granted	06/09/2000	06/09/2020 (expired)
BioCryst	Process for Preparing Substituted Cyclopentane Derivatives and Novel Crystalline Structures Thereof	US	6,576,786	Granted	06/09/2000*	06/09/2020 (expired)

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Process for Preparing (-)- (1S,4R) N-Protected 4-Amino-2-Cyclopentene-1-Carboxylate Esters	Japan	4532801	Granted	06/09/2000	06/09/2020 (expired)
BioCryst	Process for Preparing (-)- (1S,4R) N-Protected 4-Amino-2-Cyclopentene-1-Carboxylate Esters	Philippines	1-2000-001715	Granted	06/09/2000	06/09/2020 (expired)
BioCryst	Process for Preparing (-)- (1S,4R) N-Protected 4-Amino-2-Cyclopentene-1-Carboxylate Esters	US	6,495,711	Granted	06/09/2000*	06/09/2020 (expired)
BioCryst	Preparation of Substituted Cyclopentane and Cyclopentene Compounds and Certain Intermediates	US	6,762,316	Granted	06/28/2000	06/28/2020 (expired)

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst*	Inhibitors of Nucleoside Metabolism	Australia	749098	Granted	10/14/1998	10/14/2018 (expired)
BioCryst*	Inhibitors of Nucleoside Metabolism	Canada	2305760	Granted	10/14/1998	10/14/2018 (expired)
BioCryst*	Inhibitors of Nucleoside Metabolism	China	ZL98811489	Granted	10/14/1998	10/14/2018 (expired)
BioCryst*	Inhibitors of Nucleoside Metabolism	China	ZL200510092066.9	Granted	10/14/1998	10/14/2018 (expired)
BioCryst*	Inhibitors of Nucleoside Metabolism	EPO	1023308	Granted*	10/14/1998	10/14/2018 (expired)
BioCryst*	Inhibitors of Nucleoside Metabolism	Hong Kong	HK1089159	Granted	10/14/1998	10/14/2018 (expired)
BioCryst*	Inhibitors of Nucleoside Metabolism	Japan	4451983	Granted	10/14/1998	10/14/2023
BioCryst*	Inhibitors of Nucleoside Metabolism	Republic of Korea	637479	Granted	10/14/1998	10/14/2018 (expired)
BioCryst*	Inhibitors of Nucleoside Metabolism	US	5,985,848	Granted	10/14/1997*	10/14/2017 (expired)
BioCryst*	Inhibitors of Nucleoside Metabolism	US	6,066,722	Granted	10/14/1997*	10/14/2017 (expired)

*Validated in AT, BE, CH/LI, CY, DK, FI, FR, DE, GB, GR, IE, IT, LU, MC, NL, PT, ES, and SE

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst*	Inhibitors of Nucleoside Metabolism	US	6,228,847	Granted	10/14/1997*	10/14/2017 (expired)
BioCryst*	Inhibitors of Nucleoside Metabolism	US	6,492,347	Granted	10/14/1997*	10/14/2017 (expired)
BioCryst*	Inhibitors of Nucleoside Metabolism	US	6,803,455	Granted	10/14/1997*	10/14/2017 (expired)
BioCryst*	Inhibitors of Nucleoside Metabolism	US	7,211,653	Granted	10/14/1997*	10/14/2017 (expired)
BioCryst*	Inhibitors of Nucleoside Metabolism	US	7,390,890	Granted	10/14/1997*	10/14/2017 (expired)
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	Australia	776540	Granted	04/07/2000	04/07/2020 (expired)
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	Canada	2368095	Granted	04/07/2000	04/07/2020 (expired)
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	Canada	2634299	Granted	04/07/2000	04/07/2020 (expired)

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	Canada	2696826	Granted	04/07/2000	04/07/2020 (expired)
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	China	1196704C	Granted	04/07/2000	04/07/2020 (expired)
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	China	100344630C	Granted	04/07/2000	04/07/2020 (expired)
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	China	200610148465.7	Granted	04/07/2000	04/07/2020 (expired)
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	EPO	1165364	Granted*	04/07/2000	04/07/2020 (expired)

*Validated in AL, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LT, LU, LV, MC, MK, NL, PT, RO, SE, and SI

Summary of Patents and Patent Applications in BioCryst Patent Estate – November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	EPO	2077268	Granted* *Validated in AL, AT, BE, CH/EL, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LT, LU, LV, MC, MK, NL, PT, RO, SE, and SI	04/07/2000	04/07/2020 (expired)
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	Hong Kong	HK1088310	Granted	04/07/2000	04/07/2020 (expired)
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	Hong Kong	HK1116472	Granted	04/07/2000	04/07/2020 (expired)
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	Japan	4430247	Granted	04/07/2000	04/07/2025
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	Japan	5070237	Granted	04/07/2000	04/07/2020 (expired)
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	Republic of Korea	0755110	Granted	04/07/2000	04/07/2020 (expired)

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	Republic of Korea	0827118	Granted	04/07/2000	04/07/2020 (expired)
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	New Zealand	514660	Granted	04/07/2000	04/07/2020 (expired)
BioCryst*	Process for Preparing 2-Pyrroliidinyl-1H-Pyrrolo[3,2-d]Pyrimidine Inhibitors of Nucleoside Metabolism	US	6,693,193	Granted	04/07/2000	04/07/2020 (expired)
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	US	7,022,852	Granted	04/07/2000	08/16/2020 (expired)
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	US	7,211,677	Granted	04/07/2000	04/07/2020 (expired)

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst*	Process for Preparing Inhibitors of Nucleoside Metabolism	US	7,405,297	Granted	04/07/2000	04/07/2020 (expired)
BioCryst	Methods of Treating Hematologic Cancers	Australia	2008335167	Granted	12/10/2008	12/10/2028
BioCryst	Methods of Treating Hematologic Cancers	Canada	2708606	Granted	12/10/2008	12/10/2028
BioCryst	Methods of Treating Hematologic Cancers	China	20088012680.7	Granted	12/10/2008	12/10/2028
BioCryst	Methods of Treating Hematologic Cancers	China	ZL201410039689.9	Granted	12/10/2008	12/10/2028
BioCryst	Methods of Treating Hematologic Cancers	Eurasia	018415	Granted*	12/10/2008	12/10/2028
				* Maintained in Russian Federation		
BioCryst	Methods of Treating Hematologic Cancers	EPO	2564846	Granted*	12/10/2008	12/10/2028
				* Validated in FR, DE, GB, IT, NL, ES		

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Methods of Treating Hematologic Cancers	India	2383/KOLNP/2010	Pending	12/10/2008	12/10/2028
BioCryst	Methods of Treating Hematologic Cancers	Japan	5543362	Granted	12/10/2008	12/10/2028
BioCryst	Methods of Treating Hematologic Cancers	Republic of Korea	10-1545367	Granted	12/10/2008	12/10/2028
BioCryst	Methods of Treating Hematologic Cancers	New Zealand	601072	Granted	12/10/2008	12/10/2028
BioCryst	Methods of Treating Hematologic Cancers	US	16/400,414	Pending	12/10/2008	12/10/2028
BioCryst*	Inhibitors of Nucleoside Phosphorylases and Nucleosidases	Australia	258911	Granted	08/21/2003	08/21/2023
BioCryst*	Inhibitors of Nucleoside Phosphorylases and Nucleosidases	Brazil	BR20030013664.7	Pending	08/21/2003	08/21/2023
BioCryst*	Inhibitors of Nucleoside Phosphorylases and Nucleosidases	Canada	2496698	Granted	08/21/2003	08/21/2023

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst*	Inhibitors of Nucleoside Phosphorylases and Nucleosidases	China	ZL03824354.7	Granted	08/21/2003	08/21/2023
BioCryst*	Inhibitors of Nucleoside Phosphorylases and Nucleosidases	EPO	1539783	Granted*	08/21/2003	08/21/2023
				*Validated in AT, BE, BG, CY, CZ, DK, EE, FI, FR, DE, GR, HU, IE, IT, LU, MC, PT, RO, SK, SI, ES, SE, CH/LA, TR, GB, and NL		
BioCryst*	Inhibitors of Nucleoside Phosphorylases and Nucleosidases	Hong Kong	HK1085219	Granted	08/21/2003	08/21/2023
BioCryst*	Inhibitors of Nucleoside Phosphorylases and Nucleosidases	India	244822	Granted	08/21/2003	08/21/2023
BioCryst*	Inhibitors of Nucleoside Phosphorylases and Nucleosidases	Japan	4682314	Granted	08/21/2003	08/21/2023
BioCryst*	Inhibitors of Nucleoside Phosphorylases and Nucleosidases	Republic of Korea	10-1081226	Granted	08/21/2003	08/21/2023
BioCryst*	Inhibitors of Nucleoside Phosphorylases and Nucleosidases	New Zealand	538368	Granted	08/21/2003	08/21/2023

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst*	Inhibitors of Nucleoside Phosphorylases and Nucleosidases	Russian Federation	2330042	Granted	08/21/2003	08/21/2023
BioCryst*	Inhibitors of Nucleoside Phosphorylases and Nucleosidases	Singapore	110552	Granted	08/21/2003	08/21/2023
BioCryst*	5H-Pyrrrol[3,2-d]Pyrimidine Inhibitors of Nucleoside Phosphorylases and Nucleosidases	US	7,553,839	Granted	08/21/2003	12/03/2023
BioCryst*	Fused Pyrimidines as Inhibitors of Nucleoside Phosphorylases and Nucleosidases	US	8,173,662	Granted	08/21/2003	09/01/2024
BioCryst	Useful Pharmaceutical Salts of 7-[(3R,4R)-3-Hydroxy-4-Hydroxymethyl-Pyrrolidin-1-Ylmethyl]-3,5-Dihydro-Pyrrrol[3,2-d]Pyrimidin-4-One	Australia	2010230008	Granted	03/24/2010	03/24/2030

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4-Hydroxymethyl-Pyrrolidin-1-Ylmethyl]-3,5-Dihydro-Pyrrolo[3,2-d]Pyrimidin-4-One	Brazil	PI 1006534-2	Pending	03/24/2010	03/24/2030
BioCryst	Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4-Hydroxymethyl-Pyrrolidin-1-Ylmethyl]-3,5-Dihydro-Pyrrolo[3,2-d]Pyrimidin-4-One	Canada	2755950	Granted	03/24/2010	03/24/2030

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4-Hydroxymethyl-Pyrrolidin-1-ylmethyl]-3,5-Dihydro-Pyrrolo[3,2-d]Pyrimidin-4-One	China	ZL201080022925.6	Granted	03/24/2010	03/24/2030
BioCryst	Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4-Hydroxymethyl-Pyrrolidin-1-ylmethyl]-3,5-Dihydro-Pyrrolo[3,2-d]Pyrimidin-4-One	Eurasia	020931	Granted* *Maintained in Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Russian Federation, Tajikistan, and Turkmenistan	03/24/2010	03/24/2030

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4-Hydroxymethyl-Pyrrolidin-1-ylmethyl]-3,5-Dihydro-Pyrrolo[3,2-d]Pyrimidin-4-One	EPO	2411394	Granted* * Validated in ES, IT, PL, TR, CH/LI, IE, FR, DE, and GB	03/24/2010	03/24/2030
BioCryst	Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4-Hydroxymethyl-Pyrrolidin-1-ylmethyl]-3,5-Dihydro-Pyrrolo[3,2-d]Pyrimidin-4-One	Hong Kong	1170486	Granted	03/24/2010	03/24/2030

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4-Hydroxymethyl-Pyrrolidin-1-ylmethyl]-3,5-Dihydro-Pyrrolo[3,2-d]Pyrimidin-4-One	India	312836 (8012/DEL/NP/2011)	Granted	03/24/2010	03/24/2030
BioCryst	Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4-Hydroxymethyl-Pyrrolidin-1-ylmethyl]-3,5-Dihydro-Pyrrolo[3,2-d]Pyrimidin-4-One	Israel	215298	Granted	03/24/2010	03/24/2030

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4-Hydroxymethyl-Pyrrolidin-1-ylmethyl]-3,5-Dihydro-Pyrrolo[3,2-d]Pyrimidin-4-One	Japan	5766687	Granted	03/24/2010	03/24/2030
BioCryst	Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4-Hydroxymethyl-Pyrrolidin-1-ylmethyl]-3,5-Dihydro-Pyrrolo[3,2-d]Pyrimidin-4-One	Republic of Korea	10-1763672	Granted	03/24/2010	03/24/2030

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4-Hydroxymethyl-Pyrrolidin-1-ylmethyl]-3,5-Dihydro-Pyrrolo[3,2-d]Pyrimidin-4-One	Mexico	318219	Granted	03/24/2010	03/24/2030
BioCryst	Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4-Hydroxymethyl-Pyrrolidin-1-ylmethyl]-3,5-Dihydro-Pyrrolo[3,2-d]Pyrimidin-4-One	New Zealand	595590	Granted	03/24/2010	03/24/2030

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4-Hydroxymethyl-Pyrrolidin-1-ylmethyl]-3,5-Dihydro-Pyrrolo[3,2-d]Pyrimidin-4-One	Philippines	1-2011-501900	Granted	03/24/2010	03/24/2030
BioCryst	Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4-Hydroxymethyl-Pyrrolidin-1-ylmethyl]-3,5-Dihydro-Pyrrolo[3,2-d]Pyrimidin-4-One	Russian Federation	2489435	Granted	03/24/2010	03/24/2030

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4-Hydroxymethyl-Pyrrolidin-1-Ylmethyl]-3,5-Dihydro-Pyrrolo[3,2-d]Pyrimidin-4-One	Singapore	174517	Granted	03/24/2010	03/24/2030
BioCryst	Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4-Hydroxymethyl-Pyrrolidin-1-Ylmethyl]-3,5-Dihydro-Pyrrolo[3,2-d]Pyrimidin-4-One	US	8,501,753	Granted	03/24/2010	03/24/2030

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Useful Pharmaceutical Salts of 7-[(3R, 4R)-3-Hydroxy-4-Hydroxymethyl-Pyrrolidin-1-ylmethyl]-3,5-Dihydro-Pyrido[3,2-d]Pyrimidin-4-One	Vietnam	13548	Granted	03/24/2010	03/24/2030
BioCryst*	Acyclic Amine Inhibitors of Nucleoside Phosphorylases and Hydrolases	Australia	2007293774	Granted	09/07/2007	09/07/2027
BioCryst*	Acyclic Amine Inhibitors of Nucleoside Phosphorylases and Hydrolases	Canada	2662628	Granted	09/07/2007	09/07/2027
BioCryst*	Acyclic Amine Inhibitors of Nucleoside Phosphorylases and Hydrolases	China	200780040294.9	Granted	09/07/2007	09/07/2027

Summary of Patents and Patent Applications in BioCryst Patent Estate – November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst*	Acyelic Amine Inhibitors of Nucleoside Phosphorylases and Hydrolases	EPO	2057165	Granted* *Validated in AL, AT, BE, BA, BG, HR, CY, CZ, DK, EE, FI, FR, GE, GR, HU, IS, IE, IT, LV, LT, LU, MT, MK, MC, PL, PT, RO, RS, SK, SI, ES, SE, CH/LI, TR, GB, and NL	09/07/2007	09/07/2027
BioCryst*	Acyelic Amine Inhibitors of Nucleoside Phosphorylases and Hydrolases	Hong Kong	1131612	Granted	09/07/2007	09/07/2027
BioCryst*	Acyelic Amine Inhibitors of Nucleoside Phosphorylases and Hydrolases	India	287760	Granted	09/07/2007	09/07/2027
BioCryst*	Acyelic Amine Inhibitors of Nucleoside Phosphorylases and Hydrolases	Japan	5388067	Granted	09/07/2007	09/07/2027
BioCryst*	Acyelic Amine Inhibitors of Nucleoside Phosphorylases and Hydrolases	Republic of Korea	10-1433621	Granted	09/07/2007	09/07/2027

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst*	Acyelic Amine Inhibitors of Nucleoside Phosphorylases and Hydrolases	New Zealand	575365	Granted	09/07/2007	09/07/2027
BioCryst*	Acyelic Amine Inhibitors of Nucleoside Phosphorylases and Hydrolases	US	8,853,224	Granted	09/07/2007	03/29/2029
BioCryst	Inhibiting T-Cell Proliferation	US	6,660,719	Granted	12/17/2001*	02/10/2022
BioCryst	Process for the Preparation of Substituted Pyrrolidine Derivatives and Intermediates	US	7,230,119	Granted	08/25/2005*	10/10/2025
BioCryst	Carboxy Pyrrole, Process of Preparing and Use as Precursor	US	6,972,331	Granted	04/23/2003*	12/20/2023
BioCryst	Deazaguanine Analog, Preparation Thereof and Use Thereof	US	6,458,799	Granted	05/04/2001*	05/04/2021
BioCryst	Preparation of Deazaguanine Analog	US	6,780,993	Granted	02/19/2003*	02/19/2023

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Antiviral Nucleoside Analogs	Mexico	300594	Granted	01/11/2008	01/11/2028
BioCryst	Antiviral Nucleoside Analogs	US	8,440,813	Granted	01/11/2008	11/16/2028
BioCryst	Therapeutic Furopyrimidines and Thienopyrimidine ^s	US	7,429,571	Granted	10/28/2005	07/17/2026
BioCryst	Methods for the Preparation of 9-Deazapurine Derivatives	US	8,344,132	Granted	06/21/2006	03/28/2028
BioCryst	Hepatitis C Therapies	Japan	5107228	Granted	10/28/2005	10/28/2025
BioCryst	Hepatitis C Therapies	US	7,514,410	Granted	10/28/2005	10/14/2026
BioCryst	Hepatitis C Therapies	US	8,163,703	Granted	10/28/2005	10/14/2026
BioCryst	Nucleosides, Preparation Thereof and Use as Inhibitors of RNA Viral Polymerases	US	7,388,002	Granted	11/14/2002	12/31/2022

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Tetrahydrofuro [3,4-D] Dioxolane Compounds for Use in the Treatment of Viral Infections and Cancer	US	8,242,085	Granted	05/08/2008	11/16/2028
BioCryst	Aza Nucleosides, Preparation Thereof and Use as Inhibitors of RNA Viral Polymerases	US	7,560,434	Granted	06/22/2005*	08/06/2026
BioCryst	Methods and Compositions for Inhibition of Polymerase	Australia	2011315902	Granted	10/14/2011	10/14/2031
BioCryst	Methods and Compositions for Inhibition of Polymerase	Australia	2017200471	Granted	10/14/2011	10/14/2031
BioCryst	Methods and Compositions for Inhibition of Polymerase	Brazil	BR112013009029-4	Pending	10/14/2011	10/14/2031
BioCryst	Methods and Compositions for Inhibition of Polymerase	Canada	2813783	Granted	10/14/2011	10/14/2031

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Methods and Compositions for Inhibition of Polymerase	China	201180059786.9	Granted	10/14/2011	10/14/2031
BioCryst	Methods and Compositions for Inhibition of Polymerase	EPO	2627334	Granted*	10/14/2011	10/14/2031
				*Validated in AL, AT, BE, BG, CH/LI, CY, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SM, and TR		
BioCryst	Methods and Compositions for Inhibition of Polymerase	EPO	2898885	Granted*	10/14/2011	10/14/2031
				*Validated in AL, AT, BE, BG, CH/LI, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR		
BioCryst	Methods and Compositions for Inhibition of Polymerase	EPO	3345605 (17196354.9)	Granted*	10/14/2011	10/14/2031
				*Validated in GB, FR, DE, NL, CH/LI, IE, and BE		
BioCryst	Methods and Compositions for Inhibition of Polymerase	Hong Kong	HK1191565	Granted	10/14/2011	10/14/2031

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Methods and Compositions for Inhibition of Polymerase	Hong Kong	HK1212914 (16100950.9)	Granted	10/14/2011	10/14/2031
BioCryst	Methods and Compositions for Inhibition of Polymerase	Hong Kong	1257363 (18116571.3)	Granted	10/14/2011	10/14/2031
BioCryst	Methods and Compositions for Inhibition of Polymerase	India	201838039907	Pending	10/14/2011	10/14/2031
BioCryst	Methods and Compositions for Inhibition of Polymerase	Israel	225672	Granted	10/14/2011	10/14/2031
BioCryst	Methods and Compositions for Inhibition of Polymerase	Japan	5902698	Granted	10/14/2011	10/14/2031
BioCryst	Methods and Compositions for Inhibition of Polymerase	Republic of Korea	10-1850925 (10-2013-7012318)	Granted	10/14/2011	10/14/2031
BioCryst	Methods and Compositions for Inhibition of Polymerase	Mexico	348759	Granted	10/14/2011	10/14/2031
BioCryst	Methods and Compositions for Inhibition of Polymerase	Russian Federation	2599013	Granted	10/14/2011	10/14/2031

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Methods and Compositions for Inhibition of Polymerase	Russian Federation	2718690 (2016134401)	Granted	10/14/2011	10/14/2031
BioCryst	Methods and Compositions for Inhibition of Polymerase	Russian Federation	2020111042	Pending	10/14/2011	10/14/2031
BioCryst	Methods and Compositions for Inhibition of Polymerase	US	9,492,452	Granted	10/14/2011	10/14/2031
BioCryst	Methods and Compositions for Inhibition of Polymerase	US	10,022,375 (15/337,320)	Granted	10/14/2011	10/14/2031
BioCryst	Methods and Compositions for Inhibition of Polymerase	US	10,420,769 (16/013,059)	Granted	10/14/2011	10/14/2031
BioCryst	Methods and Compositions for Inhibition of Polymerase	US	16/543,079	Pending	10/14/2011	10/14/2031
BioCryst	Methods and Compositions for Treatment of Zika Virus Infection	Australia	2017229105	Pending	03/06/2017	03/06/2037
BioCryst	Methods and Compositions for Treatment of Zika Virus Infection	Canada	3016588	Pending	03/06/2017	03/06/2037

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Methods and Compositions for Treatment of Zika Virus Infection	EPO	17763837.6	Pending	03/06/2017	03/06/2037
BioCryst	Methods and Compositions for Treatment of Zika Virus Infection	Hong Kong	19126879.6	Pending	03/06/2017	03/06/2037
BioCryst	Methods and Compositions for Treatment of Zika Virus Infection	Japan	2018-566196	Pending	03/06/2017	03/06/2037
BioCryst	Methods and Compositions for Treatment of Zika Virus Infection	Mexico	MX/A/2018/010707	Pending	03/06/2017	03/06/2037
BioCryst	Methods and Compositions for Treatment of Zika Virus Infection	US	10,512,649 (16/082,437)	Granted	03/06/2017	03/06/2037
BioCryst	Methods and Compositions for Treatment of Zika Virus Infection	US	16/692,816	Allowed	03/06/2017	03/06/2037
BioCryst	Methods and Compositions for Treatment of Zika Virus Infection	Taiwan	106107257	Pending	03/06/2017	03/06/2037
BioCryst	Compositions and Methods for Inhibiting Viral Polymerase	Australia	2013249344	Granted	04/17/2013	04/17/2033

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Compositions and Methods for Inhibiting Viral Polymerase	Brazil	BR112014025909-7	Pending	04/17/2013	04/17/2033
BioCryst	Compositions and Methods for Inhibiting Viral Polymerase	Canada	2870722	Granted	04/17/2013	04/17/2033
BioCryst	Compositions and Methods for Inhibiting Viral Polymerase	China	ZL201380031507.7	Granted	04/17/2013	04/17/2033
BioCryst	Compositions and Methods for Inhibiting Viral Polymerase	Macau	J/003406	Granted (based on ZL201380031507.7, above)	04/17/2013	04/17/2033
BioCryst	Compositions and Methods for Inhibiting Viral Polymerase	EPO	2838535 (13778292.6)	Granted*	04/17/2013	04/17/2033
BioCryst	Compositions and Methods for Inhibiting Viral Polymerase	Hong Kong	HK1206627 (15107309.4)	Granted	04/17/2013	04/17/2033
BioCryst	Compositions and Methods for Inhibiting Viral Polymerase	Israel	235123	Granted	04/17/2013	04/17/2033
BioCryst	Compositions and Methods for Inhibiting Viral Polymerase	India	308689 (2525/KOLNP/2014)	Granted	04/17/2013	04/17/2033

*Validated in GB, FR, DE, NL, CH/LI, IE, and BE

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Compositions and Methods for Inhibiting Viral Polymerase	Japan	6559266 (2018-7131)	Granted	04/17/2013	04/17/2033
BioCryst	Compositions and Methods for Inhibiting Viral Polymerase	Republic of Korea	10-2014-7032192	Allowed	04/17/2013	04/17/2033
BioCryst	Compositions and Methods for Inhibiting Viral Polymerase	Republic of Korea	10-2020-7016520	Pending	04/17/2013	04/17/2033
BioCryst	Compositions and Methods for Inhibiting Viral Polymerase	Mexico	363270 (MX/a/2014/012525)	Granted	04/17/2013	04/17/2033
BioCryst	Compositions and Methods for Inhibiting Viral Polymerase	Russian Federation	2654482 (2014145857)	Granted	04/17/2013	04/17/2033
BioCryst	Compositions and Methods for Inhibiting Viral Polymerase	US	9,580,428	Granted	04/17/2013	04/17/2033
BioCryst	Compositions and Methods for Inhibiting Viral Polymerase	Argentina	20130101229	Pending	04/16/2013	04/16/2033
BioCryst	Compositions and Methods for Inhibiting Viral Polymerase	Taiwan	1664180 (102113674)	Granted	04/17/2013	04/16/2033

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Anti-Influenza Compositions and Methods	Australia	2014265483	Granted	05/14/2014	05/14/2034
BioCryst	Anti-Influenza Compositions and Methods	Canada	2911424	Pending	05/14/2014	05/14/2034
BioCryst	Anti-Influenza Compositions and Methods	EPO	2996685 (14798158.3)	Granted*	05/14/2014	05/14/2034
				*Validated in GB, FR, DE, NL, CH/L, IE, and BE		
BioCryst	Anti-Influenza Compositions and Methods	Hong Kong	HK1222560 (16110778.9)	Granted	05/14/2014	05/14/2034
BioCryst	Anti-Influenza Compositions and Methods	Japan	6417568 (2016-514060)	Granted	05/14/2014	05/14/2034
BioCryst	Anti-Influenza Compositions and Methods	US	9,499,554	Granted	05/14/2014	05/14/2034
BioCryst	Biaryl Compounds as Serine Protease Inhibitors	Australia	2002213393	Granted	10/22/2001	10/22/2021
BioCryst	Biaryl Compounds as Serine Protease Inhibitors	Canada	2426430	Granted	10/22/2001	10/22/2021

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Biaryl Compounds as Serine Protease Inhibitors	EPO	1383731	Granted*	10/22/2001	10/22/2021
				* Validated in AT, BE, CH/L, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, and TR		
BioCryst	Biaryl Compounds as Serine Protease Inhibitors	Hong Kong	HK1062676	Granted	10/22/2001	10/22/2021
BioCryst	Biaryl Compounds as Serine Protease Inhibitors	Israel	155202	Granted	10/22/2001	10/22/2021
BioCryst	Biaryl Compounds as Serine Protease Inhibitors	Israel	222773	Granted	10/22/2001	10/22/2021
BioCryst	Biaryl Compounds as Serine Protease Inhibitors	Japan	4342178	Granted	10/22/2001	10/22/2021
BioCryst	Biaryl Compounds as Serine Protease Inhibitors	Mexico	243423	Granted	10/22/2001	10/22/2021
BioCryst	Biaryl Compounds as Serine Protease Inhibitors	New Zealand	526003	Granted	10/22/2001	10/22/2021

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Biaryl Compounds as Serine Protease Inhibitors	Philippines	1-2003-500984	Granted	10/22/2001	10/22/2021
BioCryst	Biaryl Compounds as Serine Protease Inhibitors	Singapore	98519	Granted	10/22/2001	10/22/2021
BioCryst	Biaryl Compounds as Serine Protease Inhibitors	US	6,699,994	Granted	10/22/2001	11/09/2021
BioCryst	Biaryl Compounds as Serine Protease Inhibitors	US	6,936,719	Granted	10/22/2001	11/09/2021
BioCryst	Compositions and Uses of Amidine Derivatives	Australia	2015305214	Granted	08/24/2015	08/24/2035
BioCryst	Compositions and Uses of Amidine Derivatives	Canada	2959026	Pending	08/24/2015	08/24/2035
BioCryst	Compositions and Uses of Amidine Derivatives	EPO	15756791.8	Pending	08/24/2015	08/24/2035
BioCryst	Compositions and Uses of Amidine Derivatives	Hong Kong	17113101.0	Pending	08/24/2015	08/24/2035
BioCryst	Compositions and Uses of Amidine Derivatives	Japan	2017-510576	Pending	08/24/2015	08/24/2035

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Compositions and Uses of Amidine Derivatives	US	15/505,534	Allowed	08/24/2015	08/24/2035
BioCryst	Human Plasma Kallikrein Inhibitors	Australia	2015226855	Allowed	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	Australia	2020260400	Pending	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	Brazil	112016020199-0	Pending	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	Canada	2941380	Pending	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	China	201580022369.5	Allowed	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	Colombia	33324 (NC2016/0002647)	Granted	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	EPO	3113772 (15759254.4)	Granted*	03/09/2015	03/09/2035

*To be validated in AL, AT, BE, BG, CH/L, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Human Plasma Kallikrein Inhibitors	EPO	20191747.3	Pending	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	Eurasia	036251	Granted	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	Eurasia	202091668	Pending	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	Hong Kong	17106350.2	Pending	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	India	201637034289	Pending	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	Israel	247518	Pending	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	Japan	6574435 (2016-555752)	Granted	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	Japan	2019-149385	Pending	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	Republic of Korea	10-2016-7026786	Pending	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	Malaysia	P1 2016001634	Pending	03/09/2015	03/09/2035

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Human Plasma Kallikrein Inhibitors	Mexico	MX/a/2016/011468	Allowed	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	New Zealand	724250	Pending	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	New Zealand	762034	Pending	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	Philippines	1-2016-501750	Pending	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	Singapore	11201607267S	Granted	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	Singapore	10202001795X	Pending	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	South Africa	2016/06320	Pending	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	South Africa	2019/06027	Pending	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	US	10,125,102 (15/123,059)	Granted	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	US	10,329,260 (15/977,129)	Granted	03/09/2015	03/09/2035

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Human Plasma Kallikrein Inhibitors	US	10,633,345 (16/009,943)	Granted	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	US	10,689,346 (16/400,798)	Granted	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	US	16/828,755	Pending	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	US	16/828,763	Pending	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	US	16/845,833	Pending	03/09/2015	03/09/2035
BioCryst	Human Plasma Kallikrein Inhibitors	Australia	2016330926	Pending	09/30/2016	09/30/2036
BioCryst	Human Plasma Kallikrein Inhibitors	Brazil	BR112018005843-2	Pending	09/30/2016	09/30/2036
BioCryst	Human Plasma Kallikrein Inhibitors	Canada	2999164	Pending	09/30/2016	09/30/2036
BioCryst	Human Plasma Kallikrein Inhibitors	China	201680069679.7	Pending	09/30/2016	09/30/2036
BioCryst	Human Plasma Kallikrein Inhibitors	Colombia	NC2018/0004572	Pending	09/30/2016	09/30/2036

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Human Plasma Kallikrein Inhibitors	EPO	16852664.8	Pending	09/30/2016	09/30/2036
BioCryst	Human Plasma Kallikrein Inhibitors	Eurasia	201890862	Pending	09/30/2016	09/30/2036
BioCryst	Human Plasma Kallikrein Inhibitors	Hong Kong	18113965.4	Pending	09/30/2016	09/30/2036
BioCryst	Human Plasma Kallikrein Inhibitors	India	201837013301	Pending	09/30/2016	09/30/2036
BioCryst	Human Plasma Kallikrein Inhibitors	Israel	258104	Pending	09/30/2016	09/30/2036
BioCryst	Human Plasma Kallikrein Inhibitors	Japan	2018-516461	Pending	09/30/2016	09/30/2036
BioCryst	Human Plasma Kallikrein Inhibitors	Republic of Korea	10-2018-7012013	Pending	09/30/2016	09/30/2036
BioCryst	Human Plasma Kallikrein Inhibitors	Malaysia	P1 2018060405	Pending	09/30/2016	09/30/2036
BioCryst	Human Plasma Kallikrein Inhibitors	Mexico	MX/a/2018/003930	Pending	09/30/2016	09/30/2036
BioCryst	Human Plasma Kallikrein Inhibitors	New Zealand	741030	Pending	09/30/2016	09/30/2036

Summary of Patents and Patent Applications in BioCryst Patent Estate – November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Human Plasma Kallikrein Inhibitors	Philippines	1-2018-500678	Pending	09/30/2016	09/30/2036
BioCryst	Human Plasma Kallikrein Inhibitors	Singapore	11201802463Q	Granted	09/30/2016	09/30/2036
BioCryst	Human Plasma Kallikrein Inhibitors	Singapore	10202003705W	Pending	09/30/2016	09/30/2036
BioCryst	Human Plasma Kallikrein Inhibitors	South Africa	2018/02374	Pending	09/30/2016	09/30/2036
BioCryst	Human Plasma Kallikrein Inhibitors	US	10,562,850 (15/764,071)	Granted	09/30/2016	09/30/2036
BioCryst	Human Plasm Kallikrein Inhibitors	US	16/718,537	Pending	9/30/2016	9/30/2036
BioCryst	Human Plasma Kallikrein Inhibitors	Argentina	20160103021	Pending	09/30/2016	09/30/2036
BioCryst	Human Plasma Kallikrein Inhibitors	Taiwan	105131766	Pending	09/30/2016	09/30/2036
BioCryst	Prodrugs of Kallikrein Inhibitors	Australia	2017348305	Pending	10/27/2017	10/27/2037
BioCryst	Prodrugs of Kallikrein Inhibitors	Canada	3041058	Pending	10/27/2017	10/27/2037

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Prodrugs of Kallikrein Inhibitors	EPO	17864949.7	Pending	10/27/2017	10/27/2037
BioCryst	Prodrugs of Kallikrein Inhibitors	Hong Kong	620200036189	Pending	10/27/2017	10/27/2037
BioCryst	Prodrugs of Kallikrein Inhibitors	Japan	2019-522794	Pending	10/27/2017	10/27/2037
BioCryst	Prodrugs of Kallikrein Inhibitors	Israel	266223	Pending	10/27/2017	10/27/2037
BioCryst	Prodrugs of Kallikrein Inhibitors	US	10,759,759 (16/345,503)	Granted	10/27/2017	10/27/2037
BioCryst	Prodrugs of Kallikrein Inhibitors	US	16/987,721	Pending	10/27/2017	10/27/2037
BioCryst	Benzopyrazole Compounds and Analogues Thereof	Australia	2017213768	Pending	02/01/2017	02/01/2037
BioCryst	Benzopyrazole Compounds and Analogues Thereof	Brazil	BR112018015289-7	Pending	02/01/2017	02/01/2037
BioCryst	Benzopyrazole Compounds and Analogues Thereof	Canada	3011549	Pending	02/01/2017	02/01/2037

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Benzopyrazole Compounds and Analogues Thereof	China	201780621413.X	Pending	02/01/2017	02/01/2037
BioCryst	Benzopyrazole Compounds and Analogues Thereof	Colombia	NC2018/0008916	Pending	02/01/2017	02/01/2037
BioCryst	Benzopyrazole Compounds and Analogues Thereof	EPO	17748044.9	Pending	02/01/2017	02/01/2037
BioCryst	Benzopyrazole Compounds and Analogues Thereof	Eurasia	201891703	Pending	02/01/2017	02/01/2037
BioCryst	Benzopyrazole Compounds and Analogues Thereof	Hong Kong	19124745.1	Pending	02/01/2017	02/01/2037
BioCryst	Benzopyrazole Compounds and Analogues Thereof	India	201817027818	Pending	02/01/2017	02/01/2037
BioCryst	Benzopyrazole Compounds and Analogues Thereof	Israel	260545	Pending	02/01/2017	02/01/2037
BioCryst	Benzopyrazole Compounds and Analogues Thereof	Japan	2018-539873	Pending	02/01/2017	02/01/2037

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Benzopyrazole Compounds and Analogues Thereof	Republic of Korea	10-2018-7024635	Pending	02/01/2017	02/01/2037
BioCryst	Benzopyrazole Compounds and Analogues Thereof	Malaysia	P1 2018001324	Pending	02/01/2017	02/01/2037
BioCryst	Benzopyrazole Compounds and Analogues Thereof	Mexico	MX/a/2018/008869	Pending	02/01/2017	02/01/2037
BioCryst	Benzopyrazole Compounds and Analogues Thereof	New Zealand	744587	Pending	02/01/2017	02/01/2037
BioCryst	Benzopyrazole Compounds and Analogues Thereof	Philippines	1-2018-501537	Pending	02/01/2017	02/01/2037
BioCryst	Benzopyrazole Compounds and Analogues Thereof	Singapore	11201805940Q	Pending	02/01/2017	02/01/2037
BioCryst	Benzopyrazole Compounds and Analogues Thereof	South Africa	2018/05074	Pending	02/01/2017	02/01/2037
BioCryst	Benzopyrazole Compounds and Analogues Thereof	US	16/073,934	Allowed	02/01/2017	02/01/2037

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Benzopyrazole Compounds and Analogues Thereof	US	17/063,552	Pending	02/01/2017	02/01/2037
BioCryst	Benzopyrazole Compounds and Analogues Thereof	Argentina	20170100240	Pending	01/30/2017	01/30/2037
BioCryst	Benzopyrazole Compounds and Analogues Thereof	Taiwan	106103180	Pending	01/26/2017	01/26/2037
BioCryst	Imidazole-containing Inhibitors of ALK2 Kinase	Australia	2018283053	Pending	06/14/2018	06/14/2038
BioCryst	Imidazole-containing Inhibitors of ALK2 Kinase	Brazil	BR112019026517-1	Pending	06/14/2018	06/14/2038
BioCryst	Imidazole-containing Inhibitors of ALK2 Kinase	Canada	3066164	Pending	06/14/2018	06/14/2038
BioCryst	Imidazole-containing Inhibitors of ALK2 Kinase	Chile	3669-2019	Pending	06/14/2018	06/14/2038
BioCryst	Imidazole-containing Inhibitors of ALK2 Kinase	China	201880052585.8	Pending	06/14/2018	06/14/2038

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Imidazole-containing Inhibitors of ALK2 Kinase	Colombia	NC2020/0000194	Pending	06/14/2018	06/14/2038
BioCryst	Imidazole-containing Inhibitors of ALK2 Kinase	EPO	18816547.6	Pending	06/14/2018	06/14/2038
BioCryst	Imidazole-containing Inhibitors of ALK2 Kinase	Eurasia	202090052	Pending	06/14/2018	06/14/2038
BioCryst	Imidazole-containing Inhibitors of ALK2 Kinase	Hong Kong	62020018359.3	Pending	06/14/2018	06/14/2038
BioCryst	Imidazole-containing Inhibitors of ALK2 Kinase	India	202037000070	Pending	06/14/2018	06/14/2038
BioCryst	Imidazole-containing Inhibitors of ALK2 Kinase	Israel	271109	Pending	06/14/2018	06/14/2038
BioCryst	Imidazole-containing Inhibitors of ALK2 Kinase	Japan	2019-568599	Pending	06/14/2018	06/14/2038
BioCryst	Imidazole-containing Inhibitors of ALK2 Kinase	Republic of Korea	10-2020-7001054	Pending	06/14/2018	06/14/2038

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Imidazole-containing Inhibitors of ALK2 Kinase	Malaysia	P1 2019007421	Pending	06/14/2018	06/14/2038
BioCryst	Imidazole-containing Inhibitors of ALK2 Kinase	Mexico	MX/a/2019/015226	Pending	06/14/2018	06/14/2038
BioCryst	Imidazole-containing Inhibitors of ALK2 Kinase	New Zealand	760263	Pending	06/14/2018	06/14/2038
BioCryst	Imidazole-containing Inhibitors of ALK2 Kinase	Philippines	1-2019-502781	Pending	06/14/2018	06/14/2038
BioCryst	Imidazole-containing Inhibitors of ALK2 Kinase	Singapore	11201911289W	Pending	06/14/2018	06/14/2038
BioCryst	Imidazole-containing Inhibitors of ALK2 Kinase	South Africa	2020/00217	Pending	06/14/2018	06/14/2038
BioCryst	Imidazole-containing Inhibitors of ALK2 Kinase	US	16/622,816	Pending	06/14/2018	06/14/2038
BioCryst	Imidazole-containing Inhibitors of ALK2 Kinase	Argentina	20180101628	Pending	06/13/2018	06/13/2038

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Imidazole-containing Inhibitors of ALK2 Kinase	Taiwan	107120504	Pending	06/14/2018	06/14/2038
BioCryst	Substituted Benzofuran, Benzopyrrole, Benzothioephene, and Structurally Related Complement Inhibitors	Australia	2019247471	Pending	04/05/2019	04/05/2039
BioCryst	Substituted Benzofuran, Benzopyrrole, Benzothioephene, and Structurally Related Complement Inhibitors	Brazil	BR112020019183-3	Pending	04/05/2019	04/05/2039
BioCryst	Substituted Benzofuran, Benzopyrrole, Benzothioephene, and Structurally Related Complement Inhibitors	Canada	3095628	Pending	04/05/2019	04/05/2039

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP ¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date ²	Projected Expiration Date ³
BioCryst	Substituted Benzofuran, Benzopyrrole, Benzothioephene, and Structurally Related Complement Inhibitors	Chile	2578-2020	Pending	04/05/2019	04/05/2039
BioCryst	Substituted Benzofuran, Benzopyrrole, Benzothioephene, and Structurally Related Complement Inhibitors	China	Not Yet Available (National-phase entry of PCT/US2019/026054)	Pending	04/05/2019	04/05/2039
BioCryst	Substituted Benzofuran, Benzopyrrole, Benzothioephene, and Structurally Related Complement Inhibitors	Colombia	NC2020/0013840	Pending	04/05/2019	04/05/2039
BioCryst	Substituted Benzofuran, Benzopyrrole, Benzothioephene, and Structurally Related Complement Inhibitors	EPO	19780738.1	Pending	04/05/2019	04/05/2039

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Substituted Benzofuran, Benzopyrrole, Benzothioephene, and Structurally Related Complement Inhibitors	Eurasia	202092383	Pending	04/05/2019	04/05/2039
BioCryst	Substituted Benzofuran, Benzopyrrole, Benzothioephene, and Structurally Related Complement Inhibitors	Guatemala	A-2020-00153	Pending	04/05/2019	04/05/2039
BioCryst	Substituted Benzofuran, Benzopyrrole, Benzothioephene, and Structurally Related Complement Inhibitors	Hong Kong	Not Yet Available	Filing Authorized	04/05/2019	04/05/2039
BioCryst	Substituted Benzofuran, Benzopyrrole, Benzothioephene, and Structurally Related Complement Inhibitors	India	202017048130	Pending	04/05/2019	04/05/2039

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Substituted Benzofuran, Benzopyrrole, Benzothioephene, and Structurally Related Complement Inhibitors	Indonesia	P00202008112	Pending	04/05/2019	04/05/2039
BioCryst	Substituted Benzofuran, Benzopyrrole, Benzothioephene, and Structurally Related Complement Inhibitors	Israel	277787	Pending	04/05/2019	04/05/2039
BioCryst	Substituted Benzofuran, Benzopyrrole, Benzothioephene, and Structurally Related Complement Inhibitors	Japan	2020-554437	Pending	04/05/2019	04/05/2039
BioCryst	Substituted Benzofuran, Benzopyrrole, Benzothioephene, and Structurally Related Complement Inhibitors	Republic of Korea	10-2020-7031889	Pending	04/05/2019	04/05/2039

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Substituted Benzofuran, Benzopyrrole, Benzothioephene, and Structurally Related Complement Inhibitors	Malaysia	P1 2020004888	Pending	04/05/2019	04/05/2039
BioCryst	Substituted Benzofuran, Benzopyrrole, Benzothioephene, and Structurally Related Complement Inhibitors	Mexico	MX/a/2020/010508	Pending	04/05/2019	04/05/2039
BioCryst	Substituted Benzofuran, Benzopyrrole, Benzothioephene, and Structurally Related Complement Inhibitors	New Zealand	769362	Pending	04/05/2019	04/05/2039
BioCryst	Substituted Benzofuran, Benzopyrrole, Benzothioephene, and Structurally Related Complement Inhibitors	Peru	001534-2020	Pending	04/05/2019	04/05/2039

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Substituted Benzofuran, Benzopyrrole, Benzothioephene, and Structurally Related Complement Inhibitors	Philippines	1-2020-551589	Pending	04/05/2019	04/05/2039
BioCryst	Substituted Benzofuran, Benzopyrrole, Benzothioephene, and Structurally Related Complement Inhibitors	Singapore	11202008972W	Pending	04/05/2019	04/05/2039
BioCryst	Substituted Benzofuran, Benzopyrrole, Benzothioephene, and Structurally Related Complement Inhibitors	South Africa	2020/06058	Pending	04/05/2019	04/05/2039
BioCryst	Substituted Benzofuran, Benzopyrrole, Benzothioephene, and Structurally Related Complement Inhibitors	US	16/511,642	Pending	04/05/2019	04/05/2039

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Substituted Benzofuran, Benzopyrrole, Benzothioephene, and Structurally Related Complement Inhibitors	Argentina	20190100905	Pending	04/05/2019	04/05/2039
BioCryst	Substituted Benzofuran, Benzopyrrole, Benzothioephene, and Structurally Related Complement Inhibitors	GCC	2019/37319	Pending	04/03/2019	04/03/2039
BioCryst	Substituted Benzofuran, Benzopyrrole, Benzothioephene, and Structurally Related Complement Inhibitors	Lebanon	11646 (1134)	Granted	04/05/2019	04/05/2039
BioCryst	Substituted Benzofuran, Benzopyrrole, Benzothioephene, and Structurally Related Complement Inhibitors	Pakistan	206/2019	Pending	04/04/2019	04/04/2039

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Substituted Benzofuran, Benzopyrrole, Benzothioephene, and Structurally Related Complement Inhibitors	Paraguay	27283/2019	Pending	04/05/2019	04/05/2039
BioCryst	Substituted Benzofuran, Benzopyrrole, Benzothioephene, and Structurally Related Complement Inhibitors	Taiwan	1080111855	Pending	04/03/2019	04/03/2039
BioCryst	Substituted Benzofuran, Benzopyrrole, Benzothioephene, and Structurally Related Complement Inhibitors	Uruguay	38174	Pending	04/05/2019	04/05/2039
BioCryst	Cystalline Salts of a Plasma Kallikrein Inhibitor	US	PCT/US2019/059185	Pending	11/01/2019	11/01/2039
BioCryst	Cystalline Salts of a Plasma Kallikrein Inhibitor	US	10,662,160 (16/671,649)	Granted	11/01/2019	11/01/2039

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Crystalline Salts of a Plasma Kallikrein Inhibitor	US	16/784,016	Pending	11/01/2019*	11/01/2039
BioCryst	Crystalline Salts of a Plasma Kallikrein Inhibitor	Argentina	20190103187	Pending	10/31/2019	10/31/2039
BioCryst	Crystalline Salts of a Plasma Kallikrein Inhibitor	GCC	2019/38571	Pending	10/31/2019	10/31/2039
BioCryst	Crystalline Salts of a Plasma Kallikrein Inhibitor	Lebanon	11781 (3311)	Granted	10/31/2019	10/31/2039
BioCryst	Crystalline Salts of a Plasma Kallikrein Inhibitor	Pakistan	731/2019	Pending	11/01/2019	11/01/2039
BioCryst	Crystalline Salts of a Plasma Kallikrein Inhibitor	Paraguay	91831/2019	Pending	11/01/2019	11/01/2039
BioCryst	Crystalline Salts of a Plasma Kallikrein Inhibitor	Taiwan	108139655	Pending	11/01/2019	11/01/2039
BioCryst	Crystalline Salts of a Plasma Kallikrein Inhibitor	Uruguay	38438	Pending	10/31/2019	10/31/2039

Summary of Patents and Patent Applications in BioCryst Patent Estate -- November 19, 2020

Owner of IP¹	Title of IP	Country/Region	Patent or Application Number	Status	Filing Date²	Projected Expiration Date³
BioCryst	Plasma Kallikrein Inhibitors and Methods of Use Thereof in Ocular Disorders	US	PCT/US2020/027287	Pending	04/08/2020	04/08/2040
BioCryst	Dosing Regimens for Oral Complement Factor D Inhibitors	US	PCT/US2020/044037	Pending	07/29/2020	07/29/2040
BioCryst	Dosing Regimens for Oral Complement Factor D Inhibitors	Argentina	20200102161	Pending	07/31/2020	07/31/2040
BioCryst	Dosing Regimens for Oral Complement Factor D Inhibitors	GCC	2020/40189	Pending	07/28/2020	07/28/2040
BioCryst	Dosing Regimens for Oral Complement Factor D Inhibitors	Lebanon	2155	Pending	07/27/2020	07/27/2040
BioCryst	Dosing Regimens for Oral Complement Factor D Inhibitors	Pakistan	498/2020	Pending	07/29/2020	07/29/2040